The agency first approved Avycaz in 2015 to treat adults with intra-abdominal infections in combination with metronidazole. In 2016, the FDA OK’d the antibiotic to treat complicated urinary tract infections and kidney infections.
Clinicians may now use Avycaz to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, both caused by drug-resistant bacteria.
More articles on supply chain:
10 most-read supply chain stories in January
FDA approves record number of personalized medicines in 2017: 4 things to know
FDA approves treatment for C. diff-associated diarrhea: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
